Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | FPR3 | P25089 | 2/20 | 0.44 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123704 | 0.88 | DRD2 (0.53) | EPHX2MAPTACHEBACE1CD274 | |
| SCHEMBL4107606 | 0.88 | FPR3 (0.46) | FPR3FPR2ACHEBACE1CD274 | |
| SCHEMBL4129069 | 0.88 | DRD2 (0.45) | EPHX2MAPTFPR3FPR2CD274 | |
| SCHEMBL4119993 | 0.87 | KDM4E (0.51) | MAPTACHEBACE1DRD2KDM4E | |
| SCHEMBL4123912 | 0.86 | EPHX2 (0.61) | EPHX2HRH3KCNH2 | |
| SCHEMBL4119233 | 0.84 | UTS2R (0.46) | EPHX2MAPTKDM4E | |
| SCHEMBL4125793 | 0.83 | EPHX2 (0.53) | EPHX2MAPTHRH3KCNH2KDM4E | |
| SCHEMBL4119717 | 0.82 | EPHX2 (0.57) | EPHX2HRH3KCNH2CASR | |
| SCHEMBL4116393 | 0.82 | EPHX2 (0.52) | EPHX2MAPTHRH3KCNH2KDM4E | |
| SCHEMBL4124390 | 0.82 | MCHR1 (0.54) | MAPTKCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | EPHX2 1614/4885MAPT 1996/4885FPR3 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.